Charles Wu
Director Técnico/Científico/I+D en Beijing Continent Pharmaceutical Co., Ltd. .
Fortuna: - $ al 31/05/2024
Cargos activos de Charles Wu
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Director Técnico/Científico/I+D | 01/01/2020 | - |
Historial de carrera de Charles Wu
Antiguos cargos conocidos de Charles Wu.
| Empresas | Cargo | Inicio | Fin |
|---|
Formación de Charles Wu.
| University of Science & Technology of China | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
| Tulane University (Louisiana) | Masters Business Admin |
Estadísticas
Internacional
| China | 3 |
| Estados Unidos | 3 |
Operativa
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectorial
| Consumer Services | 4 |
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Bolsa de valores
- Insiders
- Charles Wu
- Experiencia
